New FDA Approval: Parsabiv DrugEtelcalcitide [Parsabiv]IndicationThe treatment of secondary hyperparathyroidism in adults on dialysis. Read More Clinical, FDA Approval, Pharmacy School, PracticeBrandon DysonFebruary 13, 2017hyperparathyroidism, PTH, parathyroid gland, etelcalcitide, Parsabiv, secondary hyperparathyroidism, calcimimetic, phosphate binder, osteoclast, bone resorption, calcium metabolism, sensipar, cinacalcet